PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. - Wikidata - awgldk - TriplyDB

PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.

PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.

http://www.wikidata.org/entity/Q37215869

about

Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders Impact of apolipoprotein E on Alzheimer's disease Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal Non-steroidal anti-inflammatory drugs and cognitive function: are prostaglandins at the heart of cognitive impairment in dementia and delirium?Insulin: an emerging treatment for Alzheimer's disease dementia?Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer's disease New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs Neuroinflammation in Alzheimer's disease Neuronal seipin knockout facilitates Aβ-induced neuroinflammation and neurotoxicity via reduction of PPARγ in hippocampus of mouse MHC mismatch inhibits neurogenesis and neuron maturation in stem cell allografts Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and Gamma Alzheimer's disease and type 2 diabetes via chronic inflammatory mechanisms Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement A network-based classification model for deriving novel drug-disease associations and assessing their molecular actions Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics.Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in rats Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer's Disease.The relationship of diet and acne: A review Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways Profiling the genes affected by pathogenic TDP-43 in astrocytes Role of the adipose PPARγ-adiponectin axis in susceptibility to stress and depression/anxiety-related behaviors.Oxaliplatin neurotoxicity involves peroxisome alterations. PPARγ agonism as preventive pharmacological approach.Alzheimer's disease: a healthcare burden of epidemic proportion.Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials Thiazolidinedione treatment and constitutive-PPARgamma activation induces ectopic adipogenesis and promotes age-related thymic involution.Using genetics to enable studies on the prevention of Alzheimer's disease Current and emerging drug treatment options for Alzheimer's disease: a systematic review.Nuclear receptors in neurodegenerative diseases.A mitocentric view of Alzheimer's disease suggests multi-faceted treatments Role of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapies Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease.Effects of low doses of pioglitazone on resting-state functional connectivity in conscious rat brain.Nuclear receptors as therapeutic targets for Alzheimer's disease WIN 55,212-2, agonist of cannabinoid receptors, prevents amyloid β1-42 effects on astrocytes in primary culture.Alzheimer's disease and the amyloid cascade hypothesis: a critical review.Lessons Learned and Potentials for Improvement in CNS Drug Development: ISCTM Section on Designing the Right Series of Experiments.Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer's Disease PPARγ-induced upregulation of CD36 enhances hematoma resolution and attenuates long-term neurological deficits after germinal matrix hemorrhage in neonatal rats.Reactive astrocytes secrete lcn2 to promote neuron death.

P2860

Q24562763-99A8BCDF-D3AB-4439-B9A5-7999C60C6C5D Q24567759-E04CAD39-3453-4E2B-8CFB-9E11860C9D6F Q26750581-1402AF78-8F14-44EA-AF45-D1C71E20125A Q26783344-65F16C23-A69A-4B7B-9428-CF934C1A09AC Q26822022-7CB00A8B-529A-40A2-B7B9-F98D06F11B06 Q26827376-004BA89C-261C-41A5-A276-17536B470C74 Q26829899-F5F0DDFC-480F-4DBF-8D82-1DFC4E06EBD6 Q26866006-F54C03C1-14FC-4236-99A5-4B416F88D9B9 Q27004226-69080602-67EB-4E15-A1E3-E4F587AD796D Q27303098-095A999B-9E39-42EA-9E1A-F61141E30CC1 Q27313884-F8931CE7-6653-429A-9383-F1B7912BB8F7 Q28075617-5E611B3C-0670-40DC-A5ED-9FBB11EF91C8 Q28086892-6FD809C8-AF90-4B47-A721-9F872C230CFE Q28394506-7CA92D8D-5004-4FF0-BB2B-11EB61177431 Q28544627-180DCBA6-2E69-4F88-96A9-804E30910847 Q30418832-8F8BDBB4-2845-4F50-BD75-8E6CC53E7075 Q30575773-4943657F-253B-4A1F-8EDD-39343DB72661 Q33628048-82F0375B-722F-4238-ACC6-5DB68F5266FF Q33718918-0DE1A6BB-B4CA-419F-BB0D-DAC7950562F3 Q33762512-55693E64-9481-4492-8F5E-B46BCED3EA13 Q33789456-AA7EB7C5-DA52-46A9-9BA6-983DB13CFD74 Q33790412-37407D1E-83FF-44FC-BD85-02ECDCB96E1F Q33921641-8DF9CBB2-933B-4BE9-BEFB-E60A3DFE61EA Q33932371-5CE1D137-99FB-4295-A0B7-60AD2CE6123E Q34014237-8E009D5D-9329-4BF5-B933-4F54DB1B9C91 Q34020483-9F0506EF-8965-4B67-8383-EF3858F92DB0 Q34038890-719D5E0B-DFC7-4FC1-8B7C-DE2EA926CAC2 Q34222721-911E504D-03BB-4419-9DF4-157571461C39 Q34580020-AEA14802-B609-4C7E-AE94-7EC5595C4EEC Q34902708-3D99A9E8-7282-4527-ABA5-2CDD90B948A4 Q34974167-071E7FCA-8966-4D8D-819E-898272547167 Q34994270-A17CFEF3-9522-44D1-B987-0367D9BAF638 Q35073600-18E63C75-1E13-4E78-B6B0-4A4ED1535289 Q35165186-1AD0C512-7ED1-495A-8C2E-BF4B3C540283 Q35601542-067BC4FC-03A9-4C3F-B3E3-BCB27ADB883C Q35855587-E507A065-3B2F-4273-B9EB-1CC92A5A7DFB Q36063631-C08B7030-210E-46BB-87B8-32CF2D552FE5 Q36081889-D5374359-DC0F-4569-A852-0B18FAE8B4F5 Q36495190-C918B595-62C5-428F-9A42-184A3AE15C0F Q36673303-D0C507AA-4EFB-43B1-B37A-3247D23348CF

P2860

PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.

http://www.wikidata.org/entity/Q37215869

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.

@en

PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.

@nl

type

label

PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.

@en

PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.

@nl

prefLabel

PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.

@en

PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.

@nl

P1433

Q37215869-95D14B70-DEE4-4896-BE58-4483E1961B86

P1476

Q37215869-8CE8F3F9-A2BA-4370-BF85-8B60B4CBB9BB

P2093

Q37215869-096D9007-4AB3-4C00-9EB4-30DB88C798A5

Q37215869-876ABF4A-811D-4D58-AB89-84DD1AC8D25A

Q37215869-8F226509-9A17-4E12-B19F-89F3F60BEED9

Q37215869-A6DA004E-5593-4658-97B7-CAFB0295BF46

P2860

Q37215869-0013998B-534A-4C6D-AC4B-D2094B275DDD

Q37215869-01E7FE36-EC3B-4DC1-8798-6A3EACD56504

Q37215869-028843D7-3D60-43A0-AD60-988517FDFD59

Q37215869-031C4A68-047F-4F98-B2F4-F3BB2EC2F262

Q37215869-065E008B-D17B-491C-9BD5-4149F30C60C8

Q37215869-09E9ADCC-DA4B-4EF1-BEDC-DCEF824C91DD

Q37215869-0A8ADD51-FD31-4451-818E-73247D6650EC

Q37215869-0B7AA7CE-A6E1-4547-93B5-1B52B062CABE

Q37215869-12135E88-8F55-4ACE-90A5-023CFA402E7C

Q37215869-165ACE83-FDED-49A7-9A1C-D5D0B7724CCC

P2888

Q37215869-D0CAFBCF-DDE0-4F5A-B547-F75DF1731C28

P304

Q37215869-5BC8A67E-DB51-4BC9-9737-833C661E9A7D

P31

Q37215869-AEB820DC-3754-42EA-8A9E-BF49D0839A3C

P356

Q37215869-FFEBB703-7E57-42D6-95EA-E5F7A5D370CC

P433

Q37215869-A60FF6FF-64D2-4817-896A-D2827191DD1C

P478

Q37215869-E42C77F5-6A66-4EB9-9C03-D9099D392F51

P577

Q37215869-FAA55FB9-7B94-4427-A242-E4E3093DDFBB

P5875

Q37215869-F62E8E73-1F50-493D-950F-CFAAD547E6A6

P6179

Q37215869-5C304626-69E7-4FEE-8026-FD27F81F3118

P698

Q37215869-BAD13490-AC97-4D27-AABA-C410BDFEDD97

P921

Q37215869-03A366FE-0570-4276-9E65-434D9565AA07

P932

Q37215869-40EB49DA-4376-4CFF-A5AC-AB9865F8A987

P356

J.NURT.2008.05.003

P1433

Neurotherapeutics

P1476

PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.

@en

P2093

Gary Landreth

http://www.w3.org/2001/XMLSchema#string

Michael Heneka

http://www.w3.org/2001/XMLSchema#string

Qingguang Jiang

http://www.w3.org/2001/XMLSchema#string

Shweta Mandrekar

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons

Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo

Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele

A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis

The coregulator exchange in transcriptional functions of nuclear receptors

Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1

Inflammation and Alzheimer's disease

Alzheimer's disease: the cholesterol connection

Nuclear hormone receptors and gene expression

P2888

j.nurt.2008.05.003

P304

481-489

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NURT.2008.05.003

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5225817

http://www.w3.org/2001/XMLSchema#string

P6179

1030614809

http://www.w3.org/2001/XMLSchema#string

P698

18625459

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

2593876

http://www.w3.org/2001/XMLSchema#string